Health knowledge made personal
Join this community!
› Share page:
Search posts:

Fosamax Whitewash Unconvincing by Jeffrey Dach MD

Posted Mar 25 2010 6:16am

fosamax induced spontaneous femur fracture bisphosphonates atypical Fosamax Study Denies Link
with Femur Fractures

by Jeffrey Dach MD

A recent NEJM article by Dennis Black MD denying a link between Fosamax and spontaneous mid-femur fractures has many doctors raising their eyebrows.  Firstly, there is the problem of conflict of interest.  The study was funded by Fosamax maker, Merck, and the authors are all on Merck's payroll. 

Above left image fosamax induce fracture courtesy of Dr Lane Nejm .

Secondly, a number of flaws in the study are brought out by Dr Elizabeth Shane who says in a NEJM Editorial : No Xray data was presented, although every patient with a fracture had xrays.  The women were on Fosamax for shorter time and lower dosage required to generate the femur fractures. The statistics of the study was questioned.

In spite of Dr Black's reassuring report, Dr Elizabeth Shane still recommends a drug holiday. This is a polite way of saying, "STOP THE DRUG".  Dr Shane says: "it is reasonable to consider drug holidays "

More Questions

Fosamax, a bad drug in litigationI have a few more questions and comments about Dr Black's NEJM report.

1) The patient data was not stratified according to T score.  The FIT trial showed increased fracture rates in patients on Fosamax with T scores greater than -2.5.  Fosamax doubled the hip fracture rate in this group (T score above -2.5) from 6 to 11. 

2) Although there were 284 hip fractures, 135 were excluded from the data for various reaons, and only 12 were accepted as spontaneous mid-femur fractures.  Whenever data is excluded from a data set, this arouses suspicion and a red flag of possible data manipulation. 

Another question:  since there was no Xray data, how can the fractures be reviewed and excluded without this?  If there was Xray review, then why wasn't this data included in the study?
3) Why do the results of Dr Dennis Black contrast with the many reported case series on Fosamax induced spontaneous femur fractures from Joseph Lane , Odvina and  Goh  (and many others).  

Dr Black's results run counter to the experience of the medical community.  Physicans are seeing and reporting more cases of atypical femur fractures on Fosamax.  We never saw these before the fosamax era.
4) Why do the results of Dr Dennis Black contrast with  bone histology studies that show abnormal bone formation on Fosamax, reporting "microdamage accumulation and reduced some mechanical properties of bone".

5) Why are these spontaneous mid-femur fractures happening at all ?  Doesn't this indicate a severe problem with the underlying bone physiology?  The bisphosphonate drug is producing abnormal, pathological bone demonstrated on histology slides.  Dr Black's report does not address this question.

6) What about reports of a link with Osteonecrosis of the Jaw , another example of fosamax disturbing bone physiology, making the bones weaker, not stronger.  Dr Black's report does not address this issue.

Bottom line: Dr Black's report is unconvincing.  Especially unconvinced are the increasing numbers of women presenting to the orthopedic surgeons with spontaneous femur fractures on fosamax.  These fractures are devastating and do not heal.

Articles with Related Content 
Fosamax and Fractured Femurs

Fosamax Induced Bilateral Femur Fractures

Fosamax, a Bad Drug in Litigation

Bisphosphonates for Osteoporosis, A Closer Look at the Data by Jeffrey Dach MD

Osteoporosis Drugs Cause Osteo-Necrosis of the Jaw by Jeffrey Dach MD

Fosamax, Actonel, Osteoporosis and Toulouse Lautrec by Jeffrey Dach MD

Links and References
Evolving Data about Subtrochanteric Fractures and Bisphosphonates Elizabeth Shane, M.D. - it is reasonable to consider drug holidays with careful observation for most patients with osteoporosis who are receiving long-term therapy
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur Dennis M. Black, Ph.D., Michael P. Kelly, M.D., Harry K. Genant, M.D., Lisa Palermo, M.A., Richard Eastell, M.D., Christina Bucci-Rechtweg, M.D., Jane Cauley, Ph.D., Ping Chung Leung, M.D., Steven Boonen, M.D., Ph.D., Arthur Santora, M.D., Anne de Papp, M.D., Douglas C. Bauer, M.D., for the Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees Conclusions The occurrence of fracture of the subtrochanteric or diaphyseal femur was very rare, even among women who had been treated with bisphosphonates for as long as 10 years. There was no significant increase in risk associated with bisphosphonate use, but the study was underpowered for definitive conclusions.


Dr. Black reports to the NEJM that he is receiving grants (to UCSF) from Merck, Novartis, Amgen, and Roche and travel reimbursements from Merck and Novartis, who also supported the research. The study was sponsored by Merck and Novartis. Several other authors work for the companies, while others consult and receive compensation for their work from the makers of bisphosphonates.
Subtrochanteric fractures- Susan Ott md

Reports of Spontaneous Femur Fractures
NEJM V358:1304-1306  March 20, 2008  Number 12
Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate Brett A. Lenart, B.S., Dean G. Lorich, M.D. ,Joseph M. Lane, M.D. ,Weill Cornell Medical College ,New York, NY 10021
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301.
Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.
J Bone Joint Surg Br 2007;89:349-353.

More Reports,87/An%20emerging%20pattern%20of%20subtrochanteric%20stress.pdf
An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?§ Ernest Beng Kee Kweka,*, Seo Kiat Goh a, Joyce Suang Bee Koh a,
Meng Ai Png b, Tet Sen Howe Department of Orthopaedic Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Singapore Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore August 2007
Injury, Int. J. Care Injured (2008) 39, 224—231
Bisphosphonates and low-impact femoral fractures: Current evidence on alendronate-fracture risk Jennifer P. Schneider, MD, PhD
J Bone Joint Surg Am. 2009 Nov;91(11):2556-61.
Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. Capeci CM, Tejwani NC.Department of Orthopaedic Surgery, New York University Hospital for Joint Diseases, 301 East 17th Street, Suite 1401, New York, NY 10003, USA.
Clin Orthop Relat Res. 2009 Jul;467(7):1921-6. Epub 2009 Feb 6.
Case reports: two femoral insufficiency fractures after long-term alendronate therapy.
Sayed-Noor AS, Sjödén GO.Department of Orthopaedic Surgery, Sundsvall Hospital, 851 86 Sundsvall, Sweden.
Drug Saf. 2009;32(9):775-85. doi: 10.2165/00002018-200932090-00002.
Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R.
Division of Clinical Pharmacology and Toxicology, Regional Pharmacovigilance Centre, University Hospitals of Geneva, Geneva, Switzerland.
Clin Orthop Relat Res. 2009 Dec 18. [Epub ahead of print]
Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate  Therapy.  Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ.
Department of Orthopedic Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1 rue Heger-Bordet, 1000, Brussels, Belgium,
Bone Histology studies

Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib , Journal of Bone and Mineral Research Volume 15 Issue 4, Pages 613 - 620 Published Online: 18 Feb 2010

Tasuku Mashiba 1, Toru Hirano 1, Charles H. Turner 1, Mark R. Forwood 2, C. Conrad Johnston 3, David B. Burr, Ph.D. 1 *
1Departments of Anatomy and Cell Biology, and Orthopaedic Surgery, Biomechanics and Biomaterials Research Center, Indiana University School of Medicine, Indianapolis
It has been hypothesized that suppression of bone remodeling allows microdamage to accumulate, leading to increased bone fragility. This study evaluated the effects of reduced bone turnover produced by bisphosphonates on microdamage accumulation and biomechanical properties of cortical bone in the dog rib. Thirty-six female beagles, 1-2 years old, were divided into three groups. The control group (CNT) was treated daily for 12 months with saline vehicle. The remaining two groups were treated daily with risedronate (RIS) at a dose of 0.5 mg/kg per day or alendronate (ALN) at 1.0 mg/kg per day orally. After sacrifice, the right ninth rib was assigned to cortical histomorphometry or microdamage analysis. The left ninth rib was tested to failure in three-point bending. Total cross-sectional bone area was significantly increased in both RIS and ALN compared with CNT, whereas cortical area did not differ significantly among groups. One-year treatment with RIS or ALN significantly suppressed intracortical remodeling (RIS, 53%; ALN, 68%) without impairment of mineralization and significantly increased microdamage accumulation in both RIS (155%) and ALN (322%) compared with CNT. Although bone strength and stiffness were not significantly affected by the treatments, bone toughness declined significantly in ALN (20%). Regression analysis showed a significant nonlinear relationship between suppressed intracortical bone remodeling and microdamage accumulation as well as a significant linear relationship between microdamage accumulation and reduced toughness. This study showed that suppression of bone turnover by high doses of bisphosphonates is associated with microdamage accumulation and reduced some mechanical properties of bone.
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Sook-Bin Woo, DMD; John W. Hellstein, DDS, MS; and John R. Kalmar, DMD, PhD
Annals of Internal Med May 16, 2006 vol. 144 no. 10 753-761

Jeffrey Dach MD
4700 Sheridan Suite T
Hollywood Fl 33021

Disclaimer click here:  

The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician -- patient relationship. Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.

Link to this article

Copyright (c) 2010,11 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given.

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

Post a comment
Write a comment:

Related Searches